It has been previously reported that inhibition of human erythroid colony-forming units (CFU-E) in vitro by interleukin-1 (IL-l) is an indirect effect, occurring through the production of interferon y (IFNy). IFNy, in turn, inhibits CFU-E colony formation directly, and its inhibitory effect can be overcome by exposure to high concentrations of erythropoietin (EPO). To develop an in vitro animal model for investigating inhibition of erythropoiesis by IFNy, the effects of recombinant murine (rm) IFNy on highly purified CFU-E from the spleens of mice infected with the anemia strain of the Friend virus (FVA) were studied. rmlFNr inhibited CFU-E colony formation in a dose-dependent manner. This inhibition occurred with large (28 cell) colonies only; smaller colonies were not affected. The inhibitory effect was corrected to 72% of control by high EPO concentrations of 64 HE ANEMIA OF CHRONIC disease (ACD) is one of the most common syndromes encountered in clinical medicine.' Current investigation into the pathogenesis of ACD has focused on the role of cytokine mediators of the immune response, such as interleukin-l (IL-l), tumor necrosis factor (TNF), and the interferons (IFNs).' IL-1 is a particularly attractive candidate as a mediator of ACD. 1L-I levels in anemic rheumatoid arthritis patients are elevated when compared with those in rheumatoid arthritis patients who are not a n e m i~.~ This elevation is correlated with the degree of anemia p r e~e n t .~ IL-l also inhibits human erythroid colony formation in vitro.3
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Purified erythroid progenitor cells from the spleens of mice infected with the anemia strain of the Friend virus (FVA) have provided a useful model for studying the regulation of erythropoiesis.' To determine the utility of FVA murine erythroid progenitors as a model for evaluating the effects of IFNy on erythropoiesis, the effect of recombinant murine (rm) IFNy on inhibition of colony formation by these cells was studied, as well as the correction of this inhibition by an IFNy receptor immunoadhesin and by rhEPO.
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MATERIALS AND METHODS
IFNy and IFN-yR-l@. rm1FN-y (4.7 X lo6 U/mg protein) and rh1FN-y (32 X IO6 U/mg protein) were provided in purified form by Genentech, Inc (South San Francisco, CA). Soluble IFNy receptor immunoadhesins, consisting of the extracellular region of murine or human IFNy receptors attached to the hinge and Fc regions of human IgGl heavy chain (mIFNyR-IgG or hIFNyR-IgG, respectively), were constructed by gene fusion, expressed in transiently transfected human embryonic kidney (HEK) cells, and purified by protein A affinity chromatography, as described previously.1o The immunoadhesin produced exhibits specificity for IFNy.Io Blood, Vol83, No 4 (February 15). 1994: pp 91 1-91 5 U/mL. Murine CFU-E were then cultured with rmlFNy in the presence of a soluble murine IFNy receptor fused to the hinge and Fc domains of the human lgG, heavy chain (mlFNyR-IgG). Inhibition of CFU-E colony formation by rmlFNy (100 U/mL) was corrected by mlFNyR-lgG in a dose-dependent manner, with an approximate ICso of0.05 nmol/L, and complete or near complete correction at 0.5 nmol/L. Similarly, a human IFNyR-lgG greatly reduced the inhibitory effect of recombinant human IFNy on human CFU-E. These experiments provide an in vitro animal model for studying the inhibitory effects of IFNy on erythropoiesis and indicate that IFNyR-lgG may be a useful agent for reducing the toxicity of IFNy in vivo. This is a US government work. There am no restrictions on its use.
Preparation of murine erythroidprogenitor cells. The method is the same as the procedure described by Sawyer et al? Briefly, splenic cells were obtained from 8-to 12-week-old female CD2F, mice that had been infected 13 to 18 days previously with lo4 spleen focusforming units of FVA. These cells were then enriched by velocity sedimentation at 4°C for 4.5 hours at unit gravity using 1% to 2% bovine serum albumin (BSA; Armour Pharmaceutical CO, Kankakee, IL) linear gradients. The cells sedimenting at rates greater than 6 mm/h, which consist almost entirely of immature erythroid cells, were collected.
The cells were plated at a concentration of IO' cells/mL into Iscove's modified Dulbecco's medium (IMDM; Sigma Chemical CO, St Louis, MO) containing 30% heat-inactivated fetal calf serum (FCS; Hyclone Laboratories, Logan, UT), 1 % deionized BSA, 150 pg/mL human transferrin (iron-saturated, purity 98%; Sigma), mol/L 2-mercaptoethanol (Eastman Kodak CO, Rochester, NY), 1 For personal use only. on October 30, 2017. by guest www.bloodjournal.org From streptomycin at 40 pg/mL, rmIFNy, and IFNyR-IgG. For each experimental point, eight replicates, each with 0.2 mL of cell suspension, were cultured at 37°C for 2 days in 48-well flat-bottomed tissue culture plates (Costar, Cambridge, MA) in a high humidity 5% CO2/ 95% air incubator. The plasma clots were then collected, fixed, and stained with benzidine-hematoxylin. Erythroid colonies were enumerated, with CFU-E defined as cells giving rise to colonies of 8 to 64 hemoglobinized cells."
Preparation ofhighlypurijied human CFU-E. The method has been reported in detail by Sawada et al.I2 Briefly, 400 mL of heparinized blood was obtained from normal volunteers, after informed consent approved by the Vanderbilt University and Nashville Department of Veterans Affairs Medical Center Institutional Review Boards, and was separated over Ficoll-Hypaque (FH; 1.077 g/mL; Pharmacia Fine Chemicals, Picataway, NJ; WinthrogBreon Laboratories, New York, NY) at 400g for 25 minutes at 24°C. The lightdensity mononuclear cells were collected in a-minimal essential medium ((U-MEM; Sigma), washed, and resuspended in IMDM. T cells were depleted by sheep erythrocyte rosettingi2 Adherent cells were then depleted by overnight incubation in 75-cm2 polystyrene tissue culture flasks in IMDM with 20% FCS and 10% giant cell tumor conditioned medium (GIBCO Laboratories, Grand Island, NY) at 37°C in a 5% CO2 atmosphere.
After overnight incubation, the nonadherent cells were collected in warm MEM and underwent negative panning with CD1 lb/ OKM*I, CD2/0KT*I 1 (Ortho Diagnostic Systems, Raritan, NJ), CD45/MyI I , and CDl6/My23, as previously described,12 to remove colony-forming units granulocyte-macrophage, neutrophils, monocytes, lymphocytes, and natural killer cells. The remaining cells (which typically contain 0.34% burst-forming units-erythroid [BFU-E]") were then cultured at a concentration of 3 X 105/mL in 0.9% methylcellulose (Fisher Scientific CO, Fairlawn, NJ) with 30% FCS, I % deionized human serum albumin (HSA; American Red Cross Blood Services, Washington, DC), mol/L 2-mercaptoethanol (Eastman Kodak CO), penicillin, streptomycin, recombinant human insulin 10 U/mL (Eli Lilly CO, Indianapolis, IN), rhIL-3 50 U/mL (gift of Dr Steven Clark, Genetics Institute, Cambridge, MA), and rhEPO 2 U/mL, in 1 -mL aliquots distributed into 12-well tissue culture plates (Linbro; Flow Laboratories, Inc, McLean, VA) at 37°C in a high humidity 5% C02/95% air incubator.
After 7 days, the cells were collected in MEM. Debris and residual contaminating cells were then separated from highly purified CFU-E by centrifugation through 10% BSA. followed by centrifugation over FH and adherence in plastic flasks with 20% FCS for I hour at 37°C. This process reproducibly yields a 94% viable population of day-8 peripheral blood cells, 30% to 90% ofwhich are CFU-E."
CFU-E were cultured at concentrations of lo' cells/mL with IMDM, 15% FCS, 15% pooled human AB serum, 10% HSA or BSA, rhEPO I U/mL, penicillin, streptomycin, 1 .S mmol/L epsilon aminocaproic acid, 1.3 mg/mL fibrinogen, and 0.2 U/mL thrombin. Replicate cells were cultured with rhIFNy 1,000 U/mL and hlFNyR-lgG 100 nmol/L. Cells were cultured for 7 days at 37°C in 5% C02/95% air and were then fixed and stained with benzidinehematoxylin. Human CFU-E were defined as colonies of 8 to 49 hemoglobinized cellsi3 and each point was studied with eight replicates. Statistical comparison was by f-test.
RESULTS
Dose-response curves with rhEPO and FVA-infected erythroid cells were performed initially to select a portion ofthe curve that was not on a plateau, but had a steep decline with decreasing concentrations of the hormone. A representative response to increasing concentrations of rhEPO is shown in At the highest concentration of rhEPO that was used, 84% of the erythroid colonies consisted of 8 to 64 cells and were derived from CFU-E, whereas 16% of erythroid colonies had less than 8 erythroid cells. Both classes oferythroid progenitors responded to increasing concentrations of rhEPO with approximately the same percentage increase in additional colonies.
To determine whether rmIFNy inhibited erythroid colony formation by spleen cells from FVA-infected mice. these cells were cultured in plasma clots with 0.01 U/mL of rhEPO in the presence of rmIFNy concentrations from 100 to 10,000 U/mL. Total erythroid colony formation was significantly inhibited ( P < .01 compared with control) at all concentrations tested (Fig 2) . This was caused by inhibition of colony formation by CFU-E ( 2 8 cells/colony), because erythroid progenitors that gave rise to colonies of less than 8 cells did not appear to be significantly inhibited (Fig 2) .
Inhibition of human CFU-E colony formation by IFNy can be completely corrected by exposure to high concentrations of rhEPO in vitro.6 To determine if FVA-infected erythroid progenitor cells were responding in a manner similar to the response of human cells, this phenomenon was also evaluated in the murine system. When the cells were cultured in 0.008 U/mL or 0.02 U/mL rhEPO, the percent inhibition by rmIFNy was similar (Table 1 ). In one experiment, 64 U/mL of rhEPO increased erythroid colony formation above the control baseline (rhEPO 0.008 U/mL), whereas in the other experiment (rhEPO 0.02 U/mL), no further increase was evident. The degree of inhibition of 
CFU-E colony
formation produced by 1,000 U/mL rmIFNy in the cultures with 64 U/mL of rhEPO was significantly reduced (P < .02) compared with that found in CFU-E cultured at lower concentrations, showing that rhEPO can overcome much of the inhibitory effect of rmIFNy on CFU-E colony formation in vitro, similar to its action on human CFU-E.
To neutralize the effect of rmIFNy, a soluble murine IFNy receptor immunoadhesin (mIFNyR-IgG) was produced and the ability of this fusion protein to counter the effect of rmIFNy on CFU-E colony formation was evaluated. FVA-infected erythroid cells were cultured in the presence of 100 U/mL rmIFNy and varying concentrations of mIFNyR-IgG were added. In two experiments (Fig 3) , mIFNyR-IgG concentrations greater than 0.5 nmol/L reversed the inhibitory effect of rmIFNy almost completely and this concentration of mIFNyR-IgG had no significant inhibitory effect on CFU-E growth in the absence of rmIFNy (96.2% of control, data not shown). However, to perform molecular or cellular studies of erythropoiesis, it is useful to have an in vitro animal model available. In the study of CFU-E, it is particularly helpful, because direct investigations of highly purified human CFU-E require expensive and labor intensive procedures occupying 1.5 days to purify generate partially purified BFU-E from peripheral blood, then a 7-day culture period to generate CFU-E, and then a 7-day in vitro incubation period for terminal differentiation and final colony formation. With the FVA-infected erythroid cells all ofthis can be accomplished in 2 days, and a much greater number of erythroid progenitor cells can be obtained. The studies reported here show that EVA-infected murine spleen cells can be used for evaluating the effects of IFNy on erythropoiesis. The results obtained with murine CFU-E cultured from these cells closely replicate the results obtained with human CFU-E exposed to rhIFNy in vitross6; Table 1 For
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namely, there is a dosedependent inhibition of colony formation by rmIFNy, and this inhibitory effect is greatly reduced by very high concentrations of rhEPO. Of course, the availability of animal models for the study of potential cytokine effects in human disease does not negate the value or necessity of ultimately using a human cell system. Inhibition of human CFU-E colony formation by IL-l in vitro is mediated by IFNy and not by TNF,' whereas inhibition of murine CFU-E by IL-l has been shown to be dependent on TNF."
In addition, we have shown that, whereas rmIFNy inhibits murine CFU-E, it had very little effect on the number of erythroid colonies that have less than 8 cells. The reason for this is not known, but it could be caused by a lesser number or affinity of IFNy receptors on more mature erythroid progenitor cells, by a reduction in the second messenger capacity for IFNy, or by a limited ability to see reduced proliferation in cells that already have a smaller proliferative capacity. The mechanism by which IFNy depresses CFU-E growth is still unknown, but it could occur through a downregulation of EPO receptors or a shift in the dissociation constant that would reduce the capacity of rhEPO to interact with the erythroid cells. High concentrations of rhEPO would then be required to overcome this effect. In addition, rhEPO might downregulate IFNy receptors or shift the dissociation curve for I m y , thus reducing inhibition by this agent. Results are expressed as mean k SE of eight replicates. hlFNyR-IgG had no effect on human CFU-E colony formation in the absence of rhlFNy (50.8 k 3.3 colonies/well without hlFNyR-IgG versus 40.3 k 5.9 colonies/well with hlFNyR-IgG 100 nmol/L; P = .17).
MEANS ET AL
P < ,001 compared with cells with the same concentration of rhEPO but no rhlFNy.
t P = . l 3 compared with cells with the same concentration of rhEPO but no rhlFNy, and P < ,001 compared with cells with the same concentration of rhlFNy.
These studies also report the inhibition of IFNy's effect on CFU-E by an IFNy receptor attached to an IgG molecule that serves to greatly prolong the plasma half life beyond that of the soluble receptor by itself.2"23 Our studies show that IFNyR-IgG is a potent inhibitor of the hematopoietic effects of 1FN-y. This inhibitory effect is specific for IFNy,"
because IFNs CY and B bind to a different receptor,24 and because the IFNy receptor appears to belong to a distinct receptor family." The inhibition of IFNy by IFNyR-IgG is analogous to the effects reported with soluble IL-l recep tor,26 with the naturally occurring IL-l receptor antagonist," and with TNF receptor immunoadhesin.28 The development of agents such as IFNyR-IgG holds out the hope of developing therapies directed at specific cytokines, as our understanding of the roles of cytokines in human disease increases, and leads to the possibility that IFNyR-IgG may be a very potent and effective agent for reducing the anemia of chronic disease. 
